

*China Pharmaceutical Guide*

中国医药市场指南

**Third Edition (2008)**

*Written by:*

**James J. Shen, MBA**

**Published by WiCON International Group**

**WiCON International Group**

407 Wickes Road, Bushkill, PA 18324, USA

Tel: (570) 588-3854 Fax: (702) 995-3905

E-mail: [info@pharmachinaonline.com](mailto:info@pharmachinaonline.com) Internet: [www.pharmachinaonline.com](http://www.pharmachinaonline.com)

China Office

Suite 17D, Building B, Oriental Kenzo Plaza

48 Dongzhimenwai Dajie, Dongcheng District, Beijing 100027, China

Tel: +86 10 84476010/11 Fax: +86 10 84476110

E-mail: [info@pharmachinaonline.com](mailto:info@pharmachinaonline.com)

**Copyright © 2008 by WiCON International Group**

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means - electronic magnetic tape, mechanical, photocopying, recording or otherwise - without prior permission of the copyright owner.

## ABOUT THE AUTHOR

China Pharmaceutical Guide is authored by James J. Shen, a veteran of the Chinese healthcare industry and market, who has dedicated his entire 20-year career to pharmaceutical businesses in China.

James Shen has rich operational and senior level management experience on China's healthcare businesses in the capacities of a senior consultant to multinational pharmaceutical companies, a manager of joint venture projects and companies, a business development executive, an entrepreneur, and most recently a publisher.



James Shen started his career in the pharmaceutical industry in 1987 when he joined Beijing Ciba-Geigy Pharmaceutical Ltd. (now Beijing Novartis) as Assistant to the General Manager. While he studied MBA in England in various periods of 1980s, he worked as an editorial consultant for Scrip/PJB Publications, IMS and Financial Times Business Information on China's healthcare news.

In 1991, he founded WiCON International Ltd. in the USA to provide strategic consulting and competitive intelligence to international healthcare companies in order to assist and facilitate their market entry into China. He has worked with many large and mid-size international pharmaceutical companies on a diverse range of projects including entry strategy development, strategic alliances and joint ventures, marketing and distribution agreements, product registration and clinical trials, licensing and technology transfer, API sourcing, and M&A due diligence. His clients include *Pfizer*, *GD Searle*, *IVAX*, *Glaxo-SmithKline*, *Novartis*, *Sanofi-Synthelabo*, *TEVA*, *Taro*, *Ajinomoto*, *AL Pharma*, *IMS*, *Medical Economics/PDR*, *Mylan Pharmaceuticals*, *Polichem*, and *Merrill Lynch*.

As an entrepreneur, James Shen co-founded *Beijing Jicai Pharmaceutical Technologies Ltd.* in 1992, one of the first private pharmaceutical research institutions in China, and took over its management in 2001. He is also a co-founder of *Nanjing Zinox Pharmaceutical Co. Ltd.*, an emerging generic pharmaceutical company in China.

James Shen was the Managing Editor of the well-known *IMS China Update*, a monthly newsletter covering China's pharmaceutical market co-published by IMS and WiCON. He authored many China healthcare business publications in English throughout 1990s, including *Marketing Pharmaceuticals in China*, *Guide to Pharmaceutical Research Institutions in China*, and *Directory of Bulk Pharmaceutical Manufacturers & Products in China*.

In early 2006, following a restructure of his businesses, James Shen founded ***Pharma China***, now the most influential English media on China's pharmaceutical industry and market which is subscribed by most multinational pharmaceutical companies, CROs, consulting companies and investment banking firms active in China.

James Shen was educated in China, Europe and the USA at university and postgraduate levels, and received an MBA from the University of Exeter (UK) in 1990.

He is now based in the USA near New York City, New Jersey, Philadelphia and Washington DC, with frequent visits to China, Singapore and Europe. He continues to be active in strategic consulting with multinational pharmaceutical companies at the headquarter and regional head office levels.

## PREFACE

Despite the enormous business opportunities and growth prospects offered by China's healthcare sector, I've witnessed and experienced countless regulatory and business environmental changes, which has frequently caused painful business difficulties, frustrations and downfalls, in my past 20 years of work in the sector as a consultant, manager and entrepreneur.

The ever-changing legal and market environments in China healthcare present the single biggest challenge to companies and executives operating in the sector. Naturally, many operational level issues and problems in the country also pose significant dangers to successful businesses.

Despite these challenges and difficulties, the Chinese pharmaceutical industry and market have achieved remarkable growth in the past two decades. The sector is generally developing towards a positive direction in the sense that it continues to grow steadily, its regulatory regime has become increasingly compatible with international standards with improving transparency, once rampant corruption is being tackled, its ongoing consolidation will eventually help establish order and stability, and the country's new healthcare reform will ultimately contribute to a more stable and healthier market environment.

There are success stories from all categories of players, whether they are foreign or local, large or small, newcomer or established, private or state-owned. However, to be one of the success stories require a thorough understanding of the sector, ability to face and tackle challenges, flexibility to deal with changes, and skills to maneuver through complex situations.

It has been my wish to put my experience and observation in the past 20 years operating in almost every aspect of China's pharmaceutical business into a publication, which will serve as a one-stop reference to anyone seeking to enter or operating in the Chinese pharmaceutical market. ***Packed with hard-to-find current data and the author's expert knowledge from years of hard-earned experience in the industry, its comprehensiveness, practicality, insight, reliable data and analysis, and up-to-date information, are the features which sets this the guide apart from other publications with similar titles.***

This Guide is written based on my past experience, interviews with relevant industry experts and government officials, articles from Pharma China, information obtained from or published by Chinese government agencies, information obtained from or published by independent pharmaceutical industry associations, reliable data and information released exclusively to WiCON for publication from various reputable market research and consulting firms, information from other trustworthy trade journals and newspapers, related information found on the internet, and a large in-house information collection by WiCON International Group accumulated since 1986.

## **About China Pharmaceutical Guide 2008 (3<sup>rd</sup> Edition)**

In this Guide, we will take our readers through some historical backgrounds, and the reform and development path that China's pharmaceutical sector has undergone since 1978. We will then discuss the varying estimates on the size of China's pharmaceutical markets (both ethical and OTC), and its different market segments, as well as drug consumption patterns in terms of therapeutic applications, regional differences, market shares between local and foreign companies, and more.

Contemporary challenges facing the pharmaceutical industry and market in China are reviewed, and potential opportunities are explored in the Guide. Understanding these challenges and opportunities will help foreign companies face the realities of China up close, be prepared for any turbulence ahead, and grasp the opportunities as they arise.

At present, 27 of the world's leading 30 multinational pharmaceutical companies have manufacturing and sales operations in China, and many of them have multiple operations. The Guide will review the current state of foreign investment in the Chinese pharmaceutical industry, and discuss the contemporary challenges facing international pharmaceutical companies in China.

The Guide also covers the healthcare provision and financing structure of the Chinese healthcare system, gives an overview of the Chinese pharmaceutical regulatory framework with briefings on each of the relevant important regulations, and offers introductions on each relevant government agencies with administrative and regulatory duties over the pharmaceutical industry.

Finally, the Guide includes a chapter that focuses on exploring pros and cons of various strategic approaches for market entry into China's burgeoning pharmaceutical market.

The size of the 2008 Edition of China Pharmaceutical Guide increased to over 850 pages from previously 700 pages, and its coverage was expanded significantly in the following areas:

Most industry, market and health sector data are updated with the 2007 (full year) and early 2008 figures

All regulatory changes in 2007/2008 are updated to present a clear and most up-to-date picture of the Chinese drug regulatory framework with summaries and analysis of all drug regulations in effect

An additional 100 pages of new data, information and case studies

New and expanded coverage on international regulatory cooperation, the Chinese R&D and outsourcing sector, clinical studies and practices, healthcare reform, community healthcare sector, essential drug policy, regional drug consumption patterns, and the vaccine sector.

Nine new case studies are added in the 2008 Edition. A total of 21 mini case studies in six important areas including market entry, R&D outsourcing, human

resource management, market size/information sources, legal/IPR battles and local success stories.

I would like to take the opportunity to thank all those organizations and individuals who contributed to this publication and their continued cooperation is greatly appreciated.

While every effort has been made to ensure that information in this publication is correct, no liability can be accepted for any loss incurred in any way whatsoever by any company or individual relying on the information herein. To the best of our knowledge the information given is accurate at the date of publication.

*James J. Shen*

June 8, 2007

**This page is left blank intentionally**



## TABLE OF CONTENTS

<b>ABOUT THE AUTHOR.....</b>	<b>3</b>
<b>PREFACE .....</b>	<b>5</b>
<b>TABLE OF CONTENTS .....</b>	<b>9</b>
<b>LIST OF TABLES .....</b>	<b>20</b>
<b>LIST OF CHARTS .....</b>	<b>24</b>
<b>TABLE OF ABBREVIATIONS .....</b>	<b>25</b>
<b>EXECUTIVE SUMMARY .....</b>	<b>27</b>
<b>PART I OVERVIEW OF THE CHINESE ECONOMY AND BUSINESS.....</b>	<b>35</b>
<b>Chapter I-1 Introduction .....</b>	<b>37</b>
1.1 Fast Economic Growth and Change.....	37
1.2 Integration into the World Economy .....	38
1.3 Economic Reform .....	39
1.4 WTO Entry Brought Further Reform and Regulatory Changes.....	40
1.5 Rising R&D Investments and Patent Applications.....	41
1.6 Future Outlook .....	41
<b>Chapter I-2 Demographic Trends .....</b>	<b>43</b>
2.1 Land and People.....	43
2.2 Demographic Trends.....	43
2.3 Conclusion .....	46
<b>Chapter I-3 Economic Foundations.....</b>	<b>47</b>
3.1 Agriculture .....	47
3.2 The Industrial Economy .....	48
3.3 Natural and Energy Resources .....	48
3.4 Basic Infrastructure .....	51
3.5 Chinese Legal System.....	53
3.6 Chinese Currency System .....	54
<b>Chapter I-4 Contemporary Issues and Trends .....</b>	<b>56</b>
4.1 Review of Chinese Economy in 2007.....	56
4.2 Comprehensive Changes Brought by China's WTO Entry .....	56
4.3 Complaints about China's Fulfillment of WTO Commitments.....	58
4.4 Major International Trade Issues.....	61
4.5 Contemporary Social-Economic Issues Facing China .....	64
<b>Chapter I-5 Foreign Investment: Key to Economic Growth .....</b>	<b>69</b>
5.1 Overview .....	69
5.2 Foreign Investment Laws.....	70
5.3 Recent Trends.....	70
5.4 Future Outlook .....	74

**PART II THE CHINESE PHARMACEUTICAL INDUSTRY AND MARKET.. 77**

<b>Chapter II-1 Introduction .....</b>	<b>79</b>
1.1 Definitions and Coverage.....	79
1.2 Segmentation of the Chinese Pharmaceutical Industry .....	80
1.3 A Brief History of the Modern Chinese Pharmaceutical Industry.....	82
1.4 Special Characteristics of the Chinese Pharmaceutical Industry.....	83
1.5 Evolution of the Chinese Pharmaceutical Industry .....	83
1.6 The Size of the Chinese Pharmaceutical Market.....	85
<b>Chapter II-2 The Pharmaceutical Industry .....</b>	<b>88</b>
2.1 Growth of the Chinese Pharmaceutical Industry.....	88
2.2 The Pharmaceutical Manufacturing Sector .....	94
2.3 The Biopharmaceutical Sector .....	101
2.4 The Vaccine Sector.....	108
2.5 Pharmaceutical R&D - The Local Pharmaceutical Industry .....	115
2.6 Pharmaceutical R&D and Outsourcing – Foreign Companies and CROs.....	119
2.7 M&A and Consolidation in the Chinese Pharmaceutical Industry .....	123
2.8 New Breed of Chinese Pharmaceutical Companies .....	127
2.9 Focus of the Immediate Future - 11 <sup>th</sup> Five Year Plan (2006 – 2010).....	130
2.10 Review of Chinese Drug Registrations in 2007 .....	131
<b>Chapter II-3 Foreign Investment in the Pharma Industry .....</b>	<b>133</b>
3.1 Forms of Foreign Investment .....	133
3.2 Areas of Encouragement and Restrictions for Foreign Investment in the Pharma Industry....	133
3.3 Growth of Foreign Investment .....	137
3.4 Contemporary Trend for Foreign Investment in the Pharmaceutical Industry .....	142
<b>Chapter II-4 Intellectual Property Rights .....</b>	<b>150</b>
4.1 Pharmaceutical Patent Protection .....	150
4.2 Administrative Protection of Pharmaceuticals (APP) .....	154
4.3 Data Exclusivity .....	160
4.4 Counterfeit Drugs.....	160
4.5 Patent and Trademark Registration .....	162
4.6 Patent and IP strategies for China .....	163
<b>Chapter II-5 Import Tariffs and Tax Issues .....</b>	<b>166</b>
5.1 Drug Import Custom Duty .....	166
5.2 Major Tax Categories for FIEs and Foreigners .....	166
<b>Chapter II-6 The Ethical Pharmaceutical Market.....</b>	<b>171</b>
6.1 Market Size .....	171
6.2 Growth Forecasts and Future Outlook .....	171
6.3 Special Characteristics of the Chinese Ethical Pharmaceutical Market .....	172
6.4 The Hospital Sector.....	173
6.5 The Retail Pharmacy Sector.....	175
6.6 The Urban vs. Rural Ethical Pharmaceutical Market.....	178
6.7 Rising Importance of the “Third Terminal Market” and Community Healthcare Sectors .....	181

<b>Chapter II-7 The OTC Pharmaceutical Market .....</b>	<b>183</b>
7.1 Market Size .....	183
7.2 Regulatory Progress on OTC Drugs .....	184
7.3 The Rise of Retail Pharmacies .....	185
7.4 Rising Trend of Self-medication .....	186
7.5 Enthusiastic Pharmaceutical Industry Seeks to Expand into OTC Drug Market .....	187
<b>Chapter II-8 The Bulk Drug/API sector .....</b>	<b>190</b>
8.1 API Producers .....	190
8.2 API Products and Output .....	190
8.3 Export Sales .....	191
8.4 Regulatory Compliance.....	192
8.5 Pharma Companies Face Challenge under New Environmental Regulations.....	192
8.6 Technological Strength.....	193
8.7 Comparisons with India's API industry .....	193
8.8 Accelerating Revenue Growth – A Review of Chinese API Sector Performance .....	194
8.9 Latest Trends and Challenges.....	196
<b>Chapter II-9 Pharmaceutical Import and Export.....</b>	<b>197</b>
9.1 Overview.....	197
9.2 Import of Medicines and Health Products.....	200
9.3 Export of Pharmaceuticals and Health Related Products .....	202
9.4 Leading Western Medicine Importers and Exporters in 2007 .....	206
9.5 Trends and Outlook.....	207
<b>PART III PHARMACEUTICAL REGULATORY FRAMEWORK .....</b>	<b>209</b>
<b>Chapter III-1 Overview .....</b>	<b>211</b>
<b>Chapter III-2 Important Laws and Regulations .....</b>	<b>213</b>
2.1 The Drug Administration Law of the People's Republic of China .....	213
2.2 Regulations for Implementation of the Drug Administration Law of the PRC .....	213
2.3 Other Regulations Governed under the <i>Drug Administration Law (2001)</i> .....	213
2.4 Other Laws and Regulations .....	216
<b>Chapter III-3 Major Government Agencies in the Pharma Field.....</b>	<b>218</b>
3.1 State Food and Drug Administration of China (SFDA) .....	218
3.2 National Development and Reform Commission (NDRC).....	225
3.3 The Ministry of Health.....	229
3.4 Ministry of Labor and Social Security .....	230
3.5 State-owned Assets Supervision and Administration Commission (SASAC).....	230
3.6 State Administration of Traditional Chinese Medicine (SATCM) .....	231
3.7 National Population and Family Planning Commission (NPFPC).....	232
<b>Chapter III-4 Pharmaceutical Industry Associations in China.....</b>	<b>234</b>
4.1 China Pharmaceutical Industry Association (CPIA) .....	234
4.2 China Biochemical Pharmaceutical Industry Association (CBPIA) .....	235
4.3 China Chamber of Commerce of Medicine and Health Product Importers and Exporters	

(CCCMHPIE) .....	235
4.4 China National Association of Pharmaceutical Commerce (CNAPC).....	235
4.5 R&D-based Pharmaceutical Association Committee (RDPAC) .....	235
4.6 China Pharmaceutical Packaging Association (CPPA) .....	236
4.7 China Pharmaceutical Technology Market Association (CPTMA).....	236
4.8 China Quality Association of Pharmaceuticals (CQAP) .....	236
4.9 China Medicinal Biotechnology Association (CMBA).....	236
4.10 China Pharmaceutical Association of Plant Engineering (CPAPE).....	236
4.11 China Association of Pharmaceutical Equipment (CAPE).....	236
4.12 China Association of Traditional Chinese Medicines (CATCM) .....	237
4.13 China Association of Traditional Chinese Medicine (CATCM).....	237
4.14 China Healthcare Association (CHA) .....	237
<b>Chapter III-5 Drug Regulatory Framework in China .....</b>	<b>238</b>
5.1 Pharmaceutical Manufacturer Licensing .....	238
5.2 Contract Manufacture/OEM.....	242
5.3 GMP Certification .....	245
5.4 Drug Labeling and Packaging .....	250
5.5 Pharmaceutical Distribution Licensing .....	256
5.6 Provisions for Control of Drug Circulation.....	258
5.7 Registration of Drug Products.....	260
5.8 Drug Import.....	274
5.9 Classified Control of Drug Products .....	276
5.10 Drug Advertising.....	279
5.11 Price Control of Drug Products .....	285
5.12 Post-marketing Surveillance/ADR Reporting .....	294
5.13 Counterfeit, Fake and Sub-standard Drugs .....	300
5.14 Control of Narcotics and Psychotropic Drugs.....	305
5.15 Internet Information Service and Sales of Drug Products.....	308
5.16 Provisions for Drug Prescription.....	310
5.17 GLP/Non-clinical Research.....	312
5.18 Essential Drug Lists .....	313
5.19 Pharmaceutical Technology Transfer .....	314
5.20 Drug Donation.....	318
5.21 International Regulatory Cooperation.....	319
5.22 Others .....	320
<b>PART IV HEALTHCARE PROVISION AND FINANCING .....</b>	<b>323</b>
<b>Chapter IV-1 Overview .....</b>	<b>325</b>
1.1 Improving Healthcare Provision .....	325
1.2 Falling Death Rate and Rising Life Expectancy .....	327
1.3 Composition of the Chinese Population.....	329
1.4 Current State of China's Healthcare System .....	331
1.5 Healthcare Reform .....	332
1.6 Development of Community Healthcare Sector Bottlenecked.....	337

<b>Chapter IV-2 Structure and Composition of Medical Provision.....</b>	<b>338</b>
2.1 Composition of the Chinese Medical Industry.....	338
2.2 Grade Structure of Chinese Medical Institutions .....	343
2.3 Regional Distribution of Healthcare Resources .....	344
2.4 Distribution of Healthcare Resources by Medical Specialty.....	347
2.5 Human Resources in China's Healthcare Industry.....	349
<b>Chapter IV-3 Healthcare Financing and Insurance programs .....</b>	<b>351</b>
3.1 Healthcare Financing in China.....	351
3.2 Urban Employee Basic Medical Insurance .....	356
3.3 Urban Resident Basic Medical Insurance Program.....	357
3.4 Occupational Hazard Insurance Program.....	358
3.5 Medical Assistance Program for Civil Servants.....	359
3.6 Rural Cooperative Medical System .....	360
3.7 Commercial Health Insurance.....	361
3.8 Limited Coverage of Chinese Population by Health Insurance .....	363
<b>Chapter IV-4 Measures of Medical Cost-containment.....</b>	<b>365</b>
4.1 Price Control .....	365
4.2 Drug Reimbursement List.....	367
4.3 Centralized Hospital Drug Purchase Tenders.....	369
4.4 Essential Drug System .....	372
4.5 Other Cost-containment Measures.....	375
<b>Chapter IV-5 Contemporary Trends and Issues in Health sector.....</b>	<b>377</b>
5.1 Contemporary Issues and Challenges .....	377
5.2 Recent Trends in the Health Sector .....	382
<b>PART V DISEASE AND DRUG CONSUMPTION PATTERNS .....</b>	<b>387</b>
<b>Chapter V-1 Growth of Drug Consumption and Demand.....</b>	<b>389</b>
1.1 Sharp Growth in Drug Consumption and Healthcare Expenditures.....	389
1.2 Size of the Chinese Pharmaceutical Market.....	391
1.3 Contributing Factors for Sharp Growth of Drug and Healthcare Expenditures in the Past Two Decades.....	395
1.4 The State of Health of the Chinese Population .....	397
<b>Chapter V-2 Popular Diseases and Morbidity .....</b>	<b>398</b>
2.1 Leading Diseases in Recent Years.....	398
2.2 Leading Causes of Death in 2007 .....	401
2.3 An Extensive Overview of Chronic and Epidemic Diseases in China.....	402
2.4 Unhealthy Lifestyle and Environmental Pollution as Widespread Healthcare Problem .....	411
<b>Chapter V-3 Hospital Attendance and Medical Expenses .....</b>	<b>413</b>
3.1 Composition of Medical Care System in China.....	413
3.2 Hospital Attendance .....	414
3.3 Healthcare Expenditures and Medical Expenses.....	417
<b>Chapter V-4 Hospital Drug Consumption Patterns .....</b>	<b>421</b>

4.1	Leading Drug Products in Urban Hospitals .....	421
4.2	Leading Pharmaceutical Suppliers .....	422
4.3	Patterns of Hospital Drug Purchase by Therapeutic Classes.....	423
<b>Chapter V-5 Retail Drug Consumption Patterns.....</b>		<b>427</b>
5.1	Patterns of Retail Pharmacy Sales of Medicine and Health Products .....	427
5.2	Leading Retail Pharmacy Chains in China.....	430
5.3	Analysis and Observations on Retail Pharmacy Sector.....	434
5.4	Consumption Patterns of OTC Drug Products .....	435
5.5	The Rise of the “Third Terminal Market” Sector .....	435
<b>Chapter V-6 Regional Drug Consumption Patterns.....</b>		<b>438</b>
6.1	Gap Between Cities and Rural Areas .....	438
6.2	Regional Markets for Pharmaceutical Products .....	439
6.3	Regional Hospital Markets for Drug Products .....	440
6.4	Regional Hospital Markets for Imported Drug Products.....	441
6.5	Regional Hospital Markets for JV-made Drug Products .....	441
6.6	Regional Hospital Markets for Locally-made Drug Products .....	442
<b>Chapter V-7 .....</b>		<b>444</b>
<b>Market shares of local, JV and Imported Drugs .....</b>		<b>444</b>
7.1	Hospital Market – Local vs. JV vs. Imported Drugs .....	444
7.2	Retail Pharmacy/OTC Market.....	448
7.3	Market Segments for New Drugs and Generic Drugs.....	449
7.4	Analysis of Leading Foreign Drug Companies in China .....	449
7.5	Analysis of Leading Foreign Drug Products in China .....	450
7.6	Future Trends and Outlook.....	450
<b>PART VI PHARMACEUTICAL SALES, MARKETING AND DISTRIBUTION IN CHINA.....</b>		<b>453</b>
<b>Chapter VI-1 History and Overview.....</b>		<b>455</b>
1.1	Pharmaceutical Sales and Distribution in China Before Early 1980s .....	455
1.2	The Roles of Manufacturers in Distribution under the Old System .....	456
1.3	Retailers and Their Roles under the Old System.....	456
1.4	The Breaking Up of the Old System .....	456
1.5	The Present State of the Pharmaceutical Marketing, Sales and Distribution System in China – An Overview .....	457
<b>Chapter VI-2 Major Promotional Practices and Government Affairs .....</b>		<b>461</b>
2.1	National and Local Drug reimbursement lists.....	461
2.2	Pricing of Drug Products.....	463
2.3	Centralized Hospital Drug Purchase Tenders.....	465
2.4	Product Launches .....	466
2.5	Clinical Research .....	468
2.6	Public Relations .....	468
2.7	Lobbying on Industrial Policies and Regulations.....	469

<b>Chapter VI-3 Marketing and Sales of Ethical Drugs in Urban Hospitals.....</b>	<b>471</b>
3.1 Mainstream Hospital Marketing and Sales Models .....	471
3.2 The Hospital Drug Purchase Approval Process .....	472
3.3 Hospital Drug Purchase Channels.....	473
3.4 Hospital Marketing/Sales Organization and Execution .....	474
3.5 Key Factors in Hospital Marketing and Sales .....	474
<b>Chapter VI-4 Marketing and Sales of Ethical Drugs through Urban Retail Pharmacies</b> .....	<b>476</b>
4.1 Channels of Retail Pharmacy Sales and Distribution.....	476
4.2 Process and Key Components of Retail Pharmacy Sales .....	477
4.3 Key Factors in Sales of Ethical Drugs through Retail Pharmacies .....	478
<b>Chapter VI-5 Sales &amp; Marketing of OTC Drug Products in Cities.....</b>	<b>479</b>
5.1 Channels of OTC Drug Sales.....	479
5.2 Process and Key Components of OTC Drug Sales .....	480
5.3 Key Factors in OTC Drug Sales.....	481
<b>Chapter VI-6 Sales, Marketing and Distribution of Drugs in the “Third Terminal Market”</b> .....	<b>483</b>
6.1 Pharmaceutical Sales & Distribution Channels to the “Third Terminal Market”.....	483
6.2 Sales and Marketing Strategies for the “Third Terminal Market”.....	484
6.3 Special Characteristics of the “Third Terminal Market” .....	485
<b>Chapter VI-7 Pharmaceutical Distribution .....</b>	<b>487</b>
7.1 Overview.....	487
7.2 Important Legal Requirements on Pharmaceutical Distribution .....	488
7.3 Pharmaceutical Distribution Channels in China .....	488
7.4 GSP Requirements for Pharmaceutical Distributors .....	491
7.5 Restrictions on Setting Up Pharmaceutical Warehousing Facilities.....	492
7.6 Logistics in Pharmaceutical Distribution – A Brief Overview .....	494
7.7 Recent Trends in Pharmaceutical Distribution.....	495
<b>PART VII CONTEMPORARY ISSUES, TRENDS AND OPPORTUNITIES ...</b>	<b>497</b>
<b>Chapter VII-1 Introduction.....</b>	<b>499</b>
<b>Chapter VII-2 Contemporary Issues and Trends.....</b>	<b>501</b>
2.1 Contradictions in Government Policies.....	501
2.2 Cost-containment Measures .....	502
2.3 Industry Consolidation and Restructuring.....	509
2.4 Classified Control on Ethical and OTC drugs.....	513
2.5 Changing Directions of Healthcare Reform.....	514
2.6 Government-backed Development of Urban Community Healthcare Sector .....	516
2.7 Intensive Competition among Local Pharmaceutical Companies.....	518
2.8 Rising Conflicts between Local and Multinational Companies .....	519
2.9 Increasing Awareness of Patient Rights .....	522
2.10 Rising Problem of Counterfeit Drugs.....	523

2.11	Emerging Trends in Pharmaceutical Distribution and Retailing Sectors.....	524
2.12	Future Outlook of the Chinese Pharmaceutical Industry and Market .....	528
<b>Chapter VII-3 Promising Opportunities of The Present and Future.....</b>		<b>532</b>
3.1	Continuous Growth of the Market.....	532
3.2	Hospital Market.....	533
3.3	OTC Market .....	536
3.4	Vaccines – The New Frontier for MPCs.....	537
3.5	Technology Transfer and Licensing .....	540
3.6	Opening of Pharmaceutical Distribution Sector.....	540
3.7	R&D Relocation to China by MNCs.....	541
3.8	Outsourcing.....	542
<b>Chapter VII-4 Emerging Outsourcing and Collaboration Opportunities.....</b>		<b>543</b>
4.1	Active Pharmaceutical Ingredients (API).....	544
4.2	Pharmaceutical Finished Products .....	549
4.3	Outsourcing in Pharmaceutical R&D.....	551
4.4	China as a Launch Pad for New Drugs .....	568
4.5	Rising Research Collaboration between Chinese and Foreign Companies.....	569
<b>PART VIII MARKET ENTRY STRATEGIES AND EXECUTION.....</b>		<b>573</b>
<b>Chapter VIII-1 Preparations for Market Entry Strategy .....</b>		<b>575</b>
1.1	The Need for a Market Entry Strategy .....	575
1.2	Long Term Perspective.....	575
1.3	Information Sources .....	576
1.4	Getting Expert Help .....	579
1.5	Market Research .....	579
1.6	Selecting the Right Products .....	580
<b>Chapter VIII-2 Strategic Approaches for Market Entry .....</b>		<b>582</b>
2.1	Direct Export of Finished Products.....	582
2.2	Sino-foreign Joint Ventures .....	584
2.3	Solely Foreign-owned Companies in China.....	586
2.4	Licensing and Technology Transfer .....	587
2.5	Merger & Acquisition (M&A) .....	589
<b>Chapter VIII-3 Execution of the Market Entry Strategy.....</b>		<b>592</b>
3.1	Product Registration.....	592
3.2	New Drug Clinical Trials and Patient Recruitment in China .....	594
3.3	Ethics Committee Challenges in Chinese Clinical Trials.....	596
3.4	Selection of a Local Distributor for Imported Drugs .....	599
3.5	Selection of a Chinese Partner for Sino-Foreign Pharmaceutical JV .....	600
3.6	Product Launch .....	601
3.7	Promotional Activities and Advertising .....	602
<b>Chapter VIII-4 Challenges and Realities for Operating in China .....</b>		<b>604</b>
4.1	Dealing with Chinese Style Laws .....	604



4.2	Rising Conflicts between Local and Multinational Companies .....	605
4.3	"Donations", "Contributions" and Commissions .....	605
4.4	Professional Ethics.....	605
4.5	Managing Clinical Trials in China.....	606
4.6	Bad Debt and Credit Control .....	607
4.7	Intellectual Property Protection.....	607
4.8	The Importance of Patience .....	610
4.9	The Value of Relationship.....	610
4.10	Staff Turnover and Talent Retention A Growing Problem .....	610
4.11	McKinsey: Chinese Prefer Local Products over Foreign Brands .....	611
<b>PART IX MINI CASE STUDIES .....</b>		<b>613</b>
<b>Chapter IX-1 Market Entry Case Studies.....</b>		<b>615</b>
1.1	Quest PharmaTech's Ill-fated China Venture.....	615
1.2	Ranbaxy (Guangzhou China) Ltd. (RGCL).....	616
1.3	Zuellig Pharma China – A Successful Case and Mature Business Model for China's Pharmaceutical Distribution Sector.....	619
<b>Chapter IX-2 R&amp;D Outsourcing Case Studies .....</b>		<b>622</b>
2.1	Eli Lilly: Build-Operate-Transfer?.....	622
<b>Chapter IX-3 Human Resource Management Case Studies.....</b>		<b>624</b>
3.1	AstraZeneca China: Continued Mission on People.....	624
3.2	Novartis China: <i>The learning strategy</i> .....	625
<b>Chapter IX-4 Case Study: Market Size / Data Sources .....</b>		<b>628</b>
<b>Chapter IX-5 Case Studies: Legal/IPR/Counterfeits battles .....</b>		<b>633</b>
5.1	Sankyo vs. Beijing Wansheng: First Lawsuit over Process Patent for Preparing Pharmaceutical Composites.....	633
5.2	Pfizer vs. 12 Local Drug Companies: Landmark Lawsuit over Viagra Patent.....	634
5.3	Eli Lilly vs. Beijing Ganli: Battle over Insulin .....	636
5.4	Boehringer Ingelheim vs. Chaitai Tianqing over Tiotropium Bromide.....	637
5.5	Legal Battle between Sanofi-Aventis and Jiangsu Hengrui over Docetaxel .....	638
5.6	Fake Drug Sting Operation – GSK Experience.....	639
5.7	Legal and Ethical Implications of ELAD Clinical Trial Death .....	640
<b>Chapter IX-6 Case Study: Local Success Stories.....</b>		<b>644</b>
6.1	China Resources Group – New Kingpin of Chinese Pharma is Born .....	644
6.2	3SBio – The Success Story of a Chinese Biogeneric Company.....	650
6.3	Shanghai Sunway Biotech Co. Ltd. – The Success Story of a Chinese Gene Therapy Drug Company.....	652
6.4	SinoVac Biotech – The Story of a Chinese Vaccine Developer .....	654
6.5	Zhejiang Hisun Pharmaceutical Ltd. – A Showcase for International Business Transformation of Chinese Pharmaceutical Companies.....	656
6.6	Jiangsu Hengrui Pharmaceutical – What Does the Future Hold for China's Largest Oncology Drug Firm?.....	661

6.7 Tongjitang Chinese Medicines Company – The Tale of a Fallen Wall Street Darling and One of the Earliest ‘China Concept’ Drug Stocks .....	663
---	-----

<b>PART X COMPANY PROFILES: MULTINATIONAL PHARMA COMPANIES IN CHINA.....</b>	<b>669</b>
<b>Pfizer China.....</b>	<b>671</b>
<b>AstraZeneca China .....</b>	<b>676</b>
<b>Roche China .....</b>	<b>682</b>
<b>Novartis China .....</b>	<b>687</b>
<b>Sanofi-Aventis China .....</b>	<b>696</b>
<b>Bayer Healthcare China.....</b>	<b>701</b>
<b>GlaxoSmithKline China .....</b>	<b>707</b>
<b>Merck Sharp &amp; Dhome China.....</b>	<b>714</b>
<b>Novo Nordisk China .....</b>	<b>717</b>
<b>Johnson &amp; Johnson China .....</b>	<b>720</b>
<b>Xian-Janssen Pharma.....</b>	<b>723</b>
<b>Eli Lilly China.....</b>	<b>727</b>
<b>Fresenius Kabi China .....</b>	<b>732</b>
<b>Bristol-Myers Squibb China.....</b>	<b>736</b>
<b>Baxter Healthcare China .....</b>	<b>740</b>
<b>Astellas China .....</b>	<b>745</b>
<b>Boehringer Ingelheim China .....</b>	<b>748</b>
<b>Merck KGaA/Merck Serono China .....</b>	<b>751</b>
<b>Schering-Plough China .....</b>	<b>756</b>
<b>Organon China .....</b>	<b>759</b>
<b>Eisai China .....</b>	<b>763</b>
<b>Servier China .....</b>	<b>766</b>
<b>Wyeth China.....</b>	<b>770</b>
<b>GE Healthcare China .....</b>	<b>774</b>
<b>Otsuka China .....</b>	<b>777</b>
<b>Daiichi Sankyo China.....</b>	<b>781</b>
<b>Abbott China.....</b>	<b>785</b>
<b>Beaufour Ipsen China.....</b>	<b>788</b>

---

<b>Santen China</b> .....	<b>790</b>
<b>Mitsubishi Pharma China</b> .....	<b>793</b>
<b>Takeda China</b> .....	<b>796</b>
<b>Kyowa Hakko China</b> .....	<b>798</b>
<b>Tanabe Seiyaku China</b> .....	<b>801</b>
<b>Solvay Pharma China</b> .....	<b>804</b>
<b>Ranbaxy China</b> .....	<b>806</b>
<b>TEVA China</b> .....	<b>809</b>
<b>Stada China</b> .....	<b>814</b>
<b>Zambon China</b> .....	<b>816</b>
<b>DSM China</b> .....	<b>818</b>
<b>APPENDICES</b> .....	<b>826</b>
<b>Appendix I Drug Administration Law of the People’S Republic Of China</b> .....	<b>828</b>
<b>Appendix II Regulations For Implementation Of The Drug Administration Law Of The PRC</b> .....	<b>848</b>
<b>Appendix III Regulations on Administrative Protection for Pharmaceuticals</b> .....	<b>868</b>
<b>Appendix IV Price Law of The People's Republic Of China</b> .....	<b>873</b>

---

## LIST OF TABLES

Table 2.1 Growth in the Number of Pharmaceutical Businesses in China .....	88
Table 2.2 Growth in Output Value of the Chinese Pharmaceutical Industry .....	89
Table 2.3 Growth in the Chinese Pharmaceutical Industry Revenues .....	90
Table 2.4 Growth in Profit Before Taxes of the Chinese Pharmaceutical Industry .....	90
Table 2.6 Revenues and Profits of the Chinese Pharmaceutical Industry in 2007.....	92
Table 2.7 Distributor Sales of Pharma Related Products in China 2000-2006.....	93
Table 2.8 Distributor Sales of Pharmaceutical Chemicals in China 2000-2006.....	93
Table 2.9 Distributor Sales of Formulated TCMs in China 2000-2006.....	94
Table 2.10a Distribution of Pharma Industry Sales by Sectors and Ownership in 2006.	96
Table 2.10b Distribution of Pharma Industry Profits by Sectors and Ownership in 2006 .....	96
Table 2.11 Leading Ten Chinese Pharmaceutical Companies in 2007 .....	98
Table 2.12 MNC Subsidiaries/JVs in the Leading 100 Chinese Pharma Cos in 2007 ....	99
Table 2.13 Estimated Total Sales of Major Vaccine Products in China.....	109
Table 2.14 Estimated Sales to Government-funded Vaccination Program .....	109
Table 2.15 New Vaccine Products of Selected Chinese Biotech Companies .....	112
Table 2.16 Distribution of Drug Approvals by Therapeutic Classes 01-08/2007 .....	131
Table 2.17 Distribution of Drug Approvals by Dosage forms 01-08/2007.....	132
Table 2.18 First Ten Sino-foreign Pharmaceutical Joint Ventures in China .....	137
Table 2.19 Foreign Investment in the Chinese Pharmaceutical Industry.....	138
Table 2.20 The World's Leading Pharmaceutical Companies in China.....	138
Table 2.21 Hospital Drug Sales of Leading 20 Multinationals in 2007.....	141
Table 2.22 Changing Structure of Chinese Drug Sales Channel 2003-07.....	182
Table 2.23 Estimated Size and Growth of Chinese Retail Pharmacy Market 2002-2007 .....	183
Table 2.24 Output of 24 Categories of Bulk Drugs in China in 2006 .....	190
Table 2.25 Sales Segmentation of Chinese API Sector in 2006 .....	194
Table 2.26 Net Profit Segmentation of Chinese API Sector in 2006.....	194
Table 2.27 Growth of the Chinese API/Bulk Drug Sector 2001-2007 .....	195
Table 2.28 China's Import/Export of Medicines and Health Products in 2006 (US\$ mil) .....	198

Table 2.29 China's Import/Export of Medicines and Health Products in 2007 (US\$ mil)	200
Table 2.30 Leading Five Origins for China's Imported Western Medicines in 2007.....	201
Table 2.31 Major Categories of Western Medicine Import 2003-2007 (US\$ million) ..	202
Table 2.32 Leading Western Medicine Export Products from China in 2007.....	203
Table 2.33 Leading Chinese API Export Products and Export Markets in 2007 .....	203
Table 2.34 Major Categories of Western Medicines Export in 2003-2007 (US\$ mil)...	204
Table 2.35a Leading Five Major Export Markets for China's Western Medicines in 2007	205
Table 2.35b Leading Ten Export Markets for China's WM Formulations in 2007 .....	206
Table 2.36 Leading Importers and Exporters of Western Medicines in China 2007 .....	207
Table 2.37 Leading Ten Exporters of WM Formulations in 2007 .....	207
Table 4.1 Improvement of Medical Provision in China .....	325
Table 4.2a Comparisons of Healthcare Provision between China and Other Countries(1)	326
Table 4.2b Comparisons of Healthcare Provision between China and Other Countries (2)	326
Table 4.3 Birth, Death and Population Natural Growth Rate.....	327
Table 4.4 Rising Life Expectancy of the Chinese Population.....	328
Table 4.5 Composition of the Chinese Population by Sex.....	329
Table 4.6 Composition of the Chinese Population by Age .....	330
Table 4.7 Composition of the Chinese Population by Education.....	330
Table 4.8 Medical Institutions by Specialties and Affiliations.....	339
Table 4.9 Inpatient Beds of Medical Institutions by Specialties and Affiliations .....	340
Table 4.10a Share of Non-Profit and For-Profit Medical Institutions in 2007.....	341
Table 4.10b Share of Medical Institutions by Ownership in 2007.....	341
Table 4.11a Share of Inpatient Beds of Medical Institutions in 2007 .....	342
Table 4.11b Share of Inpatient Beds of Medical Institutions in 2007 .....	342
Table 4.12 Number of Medical Institutions by Grade in 2007.....	343
Table 4.13 Regional Population Distribution in China .....	344
Table 4.14 Regional Distribution of Medical Institutions and Inpatient Beds in 2007..	345
Table 4.15 Regional Distribution of Healthcare Professionals in 2007 .....	346
Table 4.16 Distribution of Inpatient Beds by Medical Specialty .....	348

Table 4.17 Distribution of Physicians by Medical Specialty .....	348
Table 4.18 Healthcare Personnel in China .....	349
Table 4.19 Distribution of Healthcare Professionals in Cities and Counties .....	350
Table 4.20 Makeup of healthcare expenditures in China between 1980 and 2006.....	353
Table 4.21 China's Fiscal Investment in the Health Sector since 1980 .....	354
Table 4.22 Chinese Population with Medical Coverage (%).....	363
Table 5.1 Growth of Drug Consumption in China from 1990 .....	389
Table 5.2 Growth of Healthcare Expenditures in China from 1980 .....	390
Table 5.3 Rising Share of Per Capita Drug Expenditures in Healthcare .....	391
Table 5.4 Comparisons of Chinese Retail and Hospital Drug Sales* 2001-07 .....	392
Table 5.5 Trend of Chinese Hospital Market 2002-2007      Unit: US\$ million .....	393
Table 5.6a Segmentation of the Chinese Drug Market in 2007(1) .....	395
Table 5.6b Segmentation of the Chinese Drug Market in 2007(2) .....	395
Table 5.7a Leading Diseases by Two-week Morbidity in 2003.....	398
Table 5.7b Morbidity Rate of Chronic Diseases in 2003.....	399
Table 5.8 Leading 10 Diseases among Inpatients of Health Sector City Hospitals.....	399
Table 5.9 Leading 10 Diseases among Inpatients of Health Sector County Hospitals..	400
Table 5.10 Leading Causes of Death in Certain Regions of China in 2007 .....	401
Table 5.11 Leading Causes of Death among Chinese Males in 2007 .....	401
Table 5.12 Leading Causes of Death among Chinese Females in 2007 .....	402
Table 5.13 Composition of Medical Care Providers in China 1980 - 2007.....	413
Table 5.14 Number of Outpatient Visits and Inpatients in Medical Institutions.....	414
Table 5.15 Outpatient Visits and Inpatients by Medical Institution Type in 2007.....	415
Table 5.16 Composition of Outpatient Visits by Medical Specialties 1998-2007 .....	416
Table 5.17 Number of Outpatient Visits and Inpatients by Medical Specialties in 2007 .....	416
Table 5.18 Average Days of Hospitalization 1985-2007 .....	417
Table 5.19 Per Capita Outpatient Medical Expense in Health Sector General Hospitals .....	418
Table 5.20 Per Capita Inpatient Medical Expense in Health Sector General Hospitals	419
Table 5.21 Top 10 Drug Products by Hospital Purchase Value – 2006 .....	421
Table 5.22 Top 10 Drug Brands by Hospital Purchase Value – 2007 .....	422

Table 5.23 Top 10 Foreign Drug Brands by Hospital Purchase Value in 2006-07 .....	422
Table 5.24 Top 10 Pharmaceutical Suppliers by Hospital Drug Sales in 2006.....	423
Table 5.25 Top10 Pharmaceutical Suppliers by Hospital Drug Sales in 2007.....	423
Table 5.26 Hospital Drug Purchases by Therapeutic Classes in 2006 .....	424
Table 5.27 Hospital Drug Purchases by Therapeutic Classes in 2007 .....	424
Table 5.28 Hospital Drug Purchases by Therapeutic Classes in 2004-2007 by CPA ....	425
Table 5.29 Therapeutic Classes with Higher-Than-Average Growth in 2006 .....	425
Table 5.30 Composition of Retail Pharmacy Sales in China 2006-07 .....	427
Table 5.31 Leading Therapeutic Classes of Pharma Chemicals on the Retail Market 1H/07.....	429
Table 5.32 Changing Retail Drug Consumption Patterns 2004-07 .....	429
Table 5.33 Leading Ten Chinese Retail Pharmacy Chains in 2007 by Sales.....	430
Table 5.34 Leading Ten Chinese Retail Pharmacy Chains in 2007 by Directly-Operated Stores.....	430
Table 5.35 Leading Ten Chinese Retail Pharmacy Chains by Sales in 2007 (CNAPC)	432
Table 5.36 Chinese OTC Drug Sales by Therapeutic Classes 2005-2007 .....	435
Table 5.36 Sales of Pharmaceutical Chemical Finished Products by Regions in 2004 .	439
Table 5.37 Shares of 16 Major Chinese Regional Markets in 2006.....	440
Table 5.38 Regional Market Shares for Imported Drug Products in 2006.....	441
Table 5.39 Regional Market Shares for JV-made Drug Products in 2006 .....	442
Table 5.40 Regional Market Shares for Local Drug Products in 2006 .....	442
Table 5.41 Market Share of Imported Drugs in Ten Major Chinese Cities in 2Q, 1995	445
Table 5.42a Hospital Market Shares of Local, FIE and Foreign Companies 2002-06(CPA) .....	445
Table 5.42b Chinese Hospital Market Share Fluctuations 2002-2006 by Investor Origin .....	446
Table 5.43 Hospital Market Shares of Local, JV and Imported Drugs 2006-07 .....	447
Table 5.44 Market Shares of Local & JV/Foreign Companies in Retail Drug Sales 2004-06 .....	448
Table 5.45 Leading Ten FIE Pharma Companies by Hospital Sales in 2007.....	450

## LIST OF CHARTS

Chart 2.1 Output Value Growth of the Chinese Pharmaceutical Industry .....	89
Chart 2.2 Revenue Growth Trend of the Chinese Pharmaceutical Industry .....	90
Chart 2.3 Profit Before Taxes Growth Trend of the Chinese Pharma Industry .....	91
Chart 2.4 Profit Margin (PBT) Trend of the Chinese Pharma Industry .....	92
Chart 2.5 Segmentation of Chinese Pharma Industry Revenues in 2007 .....	92
Chart 2.6 Segmentation of Chinese Pharma Industry Profits in 2007 .....	93
Chart 2.7 Distribution of Pharma Industry Sales by Ownership Types in 2006.....	96
Chart 2.8 Distribution of Pharma Industry Profits by Ownership Types in 2006.....	97
Chart 2.9 Application Procedures Of APP .....	156
Chart 2.10 Flowchart – Revocation Procedures Of APP .....	157
Chart 2.11 Re-examination Procedures Of APP .....	158
Chart 2.12 Infringement Settlement Procedures Of APP.....	159
Chart 2.13 Size and Growth of Chinese Retail Pharmacy Market 2000-2007 .....	176
Chart 3.1 Administrative Structure of Food and Drug Regulation in China .....	219
Chart 3.2 Functional Departments and Subsidiary Organizations of the SFDA .....	225
Chart 3.3 Application and Approval Procedures for Clinical Trials .....	265
Chart 3.4 Application and approval procedure for imported drugs (1).....	267
Chart 3.5 Application and approval procedure for imported drugs (2).....	268
Chart 3.6 Supplemental Application and Approval Procedure for Imported Drugs (1)	269
Chart 3.7 Supplemental Application and Approval Procedure for Imported Drugs (2)	270
Chart 5.1 Growth of Per Capita Healthcare Expenditures in China 1990-2007 .....	390
Chart 5.2 Shares of Major Categories on the Chinese Retail Pharmacy Market in 2007 .....	428
Chart 6.1 Structure of the Chinese Pharmaceutical Distribution System in the Old Days .....	455
Chart 6.2 Approval Process of Hospital Drug Purchase .....	473
Chart 6.3 Pharmaceutical Distribution Channel in the Urban Areas .....	490
Chart 6.4 Pharmaceutical Distribution through Retail Pharmacy Chains.....	490
Chart 6.5 Pharmaceutical Distribution in Sub-urban and Rural Areas .....	491



## TABLE OF ABBREVIATIONS

ADR – Adverse Drug Reaction	NDRC – National Development and Reform Commission
API – Active Pharmaceutical Ingredients	NPFPC – National Population and Family Planning Commission
APP – Administrative Protection of Pharmaceuticals	OECD – Organization for Economic Co-operation and Development
AmCham – American Chamber of Commerce	OTC – Over The Counter
CNCM – China National Corporation of Medicines	QA – Quality Assurance
CNAPC – China National Association of Pharmaceutical Commerce	PRC – People’s Republic of China
CNY – Chinese Yuan	R&D – Research and Development
CRO – Contract Research Organization	RDPAC – R&D-based Pharmaceutical Association Committee
ED – Erectile Dysfunction	SATCM – State Administration of Traditional Chinese Medicine and Medicines
FDI – Foreign Direct Investment	SDA – State Drug Administration
FIEs – Foreign Invested Enterprises	SFDA – State Food and Drug Administration
GCP – Good Clinical Practices	SIPO – State Intellectual Property Office
GDP – Gross Domestic Products	SMEI – Southern Medicine Economic Institute
GLP – Good Laboratory Practices	SOE – State Owned Enterprise
GMP – Good Manufacturing Practices	SPAC – State Pharmaceutical Administration of China
GSP – Good Sales Practices	STD – Sexually Transmitted Disease
IFPMA – International Federation of Pharmaceutical Manufacturer Associations	TCM – Traditional Chinese Medicine
JV – Joint Venture	USFDA – US Food and Drug Administration
M&A – Merger and Acquisition	VAT – Value Added Tax
MOH – Ministry of Health	WM – Western Medicine
MOLSS – Ministry of Labor and Social Security	WHO – World Health Organization
MPC – Multinational Pharmaceutical Company	WTO – World Trade Organization
MR – Medical Representative	
NBS – National Bureau of Statistics	
NCGHSR – National Coordination Group for Healthcare System Reform	

**This Page is Left Blank Intentionally**

## EXECUTIVE SUMMARY

*James J. Shen*

Continuous double-digit growth in the past two decades has convinced even the most conservative industry analysts to offer optimistic views about the future of the Chinese pharmaceutical market. Flashy news titles such as “China Seen as Fifth Biggest Drug Market by 2010”, “China to Become the Second Largest Pharmaceutical Market by 2020” and “China Could Overtake the United States as the Top Drug Market by 2050” are frequently seen in well-known papers and journals in recent years.

Indeed, these daring predictions are not unfounded and are supported by various broad economic evidences. Nevertheless, when taking a closer look at today’s reality of the pharmaceutical industry in China, one will see the mounting challenges ahead for such rosy pictures to materialize. In fact, some challenges facing the pharmaceutical industry in China threaten to derail it from the development fast track depicted by many observers.

### ***Recap of Chinese pharma industry and market in recent years***

Official statistics suggest that the total revenue of China’s pharmaceutical industry in 2006 was around CNY 500 billion (US\$64 billion) with a total net profit of CNY 40.2 billion (US\$5.2 billion), up by 17% and 10% respectively compared with the same figures in 2005. In 2007, the total output value and sales of the Chinese pharmaceutical industry surged over 20% again, reaching over CNY 680 billion and over CNY 640 billion respectively.

Despite its continued rise, the growth rate of the Chinese pharmaceutical industry slowed significantly in 2006 due to the country’s regulatory corrections, and its profit margin also fell by nearly 50%. 25.6% of the Chinese pharmaceutical companies made losses in 2006 and their total losses rose 26.2% compared with the same figure in 2005.

With impetuous regulatory corrections of the Chinese pharmaceutical sector gradually winding down in 2007, all the market growth potential depressed in 2006 found its way back. Large companies, especially R&D-based multinationals, experienced phenomenal growth last year after regulatory cleanup of the market drove out many small and irregular competitors.

WiCON’s estimate on the overall Chinese drug market (including finished Western medicines, biochemical drugs, formulated traditional Chinese medicines and herbal drugs) in 2007 was about US\$50 billion at ex-manufacturer prices, up 19.0% from US\$42 billion in 2006.

### ***Rising global importance***

With sharp growth and advancements on many fronts in 2007 as backdrop, the global importance and influence of the pharmaceutical industry in China is beginning to emerge, and therefore, it is now a good time for me to initiate this topic.

The following landmarks serve as good indicators for the rising importance of China in

the global pharmaceutical sector.

*Rapid growth of the Chinese pharmaceutical market* – Regardless of the wide ranging estimates made by different information sources on its size, China is now one of the largest drug markets, and by 2020 is likely to be the second largest market in the world.

For many MNCs, such as Eli Lilly, China is becoming a leading overseas market and will probably become their largest overseas market within a decade;

MNCs are increasingly relocating their R&D operations to China, and some, such as GSK, are moving some of their core and integrated research functions to the country;

MNCs and foreign companies are outsourcing an increasing volume of R&D and manufacturing projects from China;

China is now the dominant supplier of active pharmaceutical ingredients and intermediates to the world;

Chinese companies are investing heavily in the past year to gear up their preparations to become a major supplier of generic formulation drug products to the world;

More and more Chinese pharmaceutical companies have become listed in overseas stock markets, in particular the United States, and the resulting financial strength of these companies will help facilitate their rapid growth in China and internationally; and

Chinese companies are beginning to acquire foreign companies for fast growth and market penetration, as shown by Wuxi PharmaTech's acquisition of AppTec.

***China strives to build up an innovative drug industry as its long term goal***

I have been a long time observer of the different paths of pharmaceutical industry development adopted by China and India. The Chinese government has always stated that it wants to have an innovative pharmaceutical industry led by large and research-based companies. At the same time, it has consistently welcomed foreign investment and encouraged integration of the local industry with international companies.

To achieve its goal, the Chinese government has adopted industrial and regulatory policies that favor research-based multinationals and large domestic enterprises, and at the same time, it has improved market access for foreign companies, strengthened IP environment to foster innovation and, most recently, cleaned up the country's marketplace to ensure success of larger and innovative companies.

Because of this, China has won increasing trust and confidence from foreign companies, most notably from R&D-based multinationals, who are boosting their investments in the country not only to expand manufacturing and marketing operations, but also to move some of their critical business operations and to transfer core technologies to the country.

Today, China is well on its way to develop its pharmaceutical industry side by side with the research-based multinational pharmaceutical companies. With the ongoing restructure of the global pharmaceutical industry in the backdrop, the fate of the Chinese

pharmaceutical industry and those of R&D-based MNCs are increasingly linked together. As this bond grows stronger and deeper, it becomes a path of no return for both sides.

It is my observation that China will be, as its long term policy, committed to supporting new drug innovation as well as growth and development of research-based multinational companies in the country, while, at the same time, attempting to foster the rise of its own large and innovative companies at the same time.

On the other hand, China faces the daunting challenge of securing the essential healthcare needs of its entire people. As the country's economy continues to grow, the need for new medicines and high quality healthcare will also rise. While large domestic companies are best-positioned to fulfill the essential healthcare needs of the nation in the short- and medium-term, innovative MNCs are certainly better -suited for the task of satisfying higher level demands.

Despite short term regulatory corrections, administrative changes or healthcare reform uncertainties, the long term direction and present development path for China's pharmaceutical sector are unlikely to be altered in any significant way.

#### ***Improving and expanding business prospects for R&D-based multinationals***

In spite of the turbulent market and regulatory environment, innovative multinational pharmaceutical companies (MPCs) have managed to establish a solid foothold and accumulated their business strength in China in the past few years.

During the period, MPCs have consolidated their bases and organizations in the country, gained absolute control in their joint ventures, expanded sales and marketing networks, improved on IPR awareness and enforcement, quietly increased their influence over the Chinese government and its policies, and most importantly, successfully fostered an industrial and market environment that is now relatively more friendly to them.

While most large and mid-sized pharmaceutical companies in China would confirm that they fared much better in 2007 compared with the previous year, the executives of R&D-based multinational companies are reporting, unofficially, sharp growth of their performance in the year, largely benefiting from government policies which are generally more favorable for MPCs.

In response to such positive market environments and mounting opportunities, MPCs are boosting their positions in China through strengthening their sales and marketing network, expanding manufacturing facilities, and accelerating R&D relocations.

In late 2007, Bayer and Novartis announced ambitious plans to expand their OTC business in China, Wyeth decided to expand its Suzhou facility, Sandoz (part of Novartis) acquired a new manufacturing facility in Zhongshan, and Sanofi Aventis began construction of a new vaccine plant in Shenzhen.

Many multinational pharmaceutical companies such as Eli Lilly and GSK poured more investments into expanding their R&D operations in China in 2007, while other MNCs such as Sanofi Aventis, Merck KGaA and Novo Nordisk entered into major research deals with Chinese research institutions. It is on the rising trend for major MNCs to

relocate some of their key R&D functions to China as represented by the bold move of GSK to relocate its entire R&D on neurodegenerative diseases to China.

### ***R&D outsourcing market grows at breakneck speed***

Phenomenon growth for R&D outsourcing business was observed in the past few years. According to a recent research, the Chinese pharmaceutical R&D outsourcing market is estimated to be around CNY 4 billion annually at present with 100% growth potential in the next few years.

Leading companies in this sector have typically recorded triple-digit growth and are expanding in both their sales and business scope at astounding speed in the past few years. Strong financial support from venture capitalists, investors and the stock market will lead to fast expansion of the major players and the sector as a whole.

Despite its huge potential, the further growth of the Chinese pharmaceutical R&D outsourcing market may be limited by three factors: 1) Shortage of highly-skilled talents, 2) High upfront investment for startup companies, and 3) Relatively low IPR awareness and weakness in the IP security of local CROs.

### ***Challenges Clouding the Future ...***

Despite all the positive forecasts and encouraging trends, the pharmaceutical industry in China, including both local firms and multinationals, is facing serious challenges that may potentially jeopardize the future prospects of the pharmaceutical market in the country.

*Contradictions in Government Policies* - There is no doubt that the Chinese government's economic policies and systemic reform spurred the rise of the Chinese pharmaceutical industry and market. However, many structural problems in China's healthcare system and pharmaceutical sector remained in the past 25 years in exchange for faster short-term growth.

On the one hand, the Chinese government wants the pharmaceutical industry to develop into an internationally competitive industry with strong new drug R&D capabilities, advanced technologies, and high quality standards; but on the other hand, it has cut back state investments in the pharmaceutical industry, repeatedly slashed prices of drug products and squeezed profit margins of the pharmaceutical industry through various cost containment measures.

The government has also cut its healthcare spending sharply, forcing the medical industry to rely on profits from drug sales, hence making the pharmaceutical industry a major source of healthcare financing, and leading to many structural flaws in the healthcare system. Evidently the share of government healthcare spending in the country's total healthcare expenditures fell to 17.1% in 2004 from 36.2% in 1980. Meanwhile, the self-paid healthcare expenditures of urban Chinese residents rose 9.6 times between 1993 and 2005.

Healthcare expenditures as a percentage of China's GDP had been falling since 2003 and it was down to 4.82% in 2007 from 5.7% in 2004. The growth of healthcare

consumption obviously lags behind that of the country's GDP.

*Changing Directions of Healthcare Reform* - A survey carried out by China Youth Daily in August 2005 found over 90% of the people in China were dissatisfied with the reform to the country's healthcare system in the previous 10 years. A survey by the National Bureau of Statistics (NBS) released on January 2008 showed again that rising medical costs have become the top concern of Chinese people. A heated discussion about China's healthcare reform began in May 2005 following the publication of a report by the Development Research Center under the State Council that concludes China's healthcare reform in the past two decades was largely unsuccessful.

Consequently, the future direction of China's healthcare reform has now become a subject of heated public debate involving ordinary people, government officials, representatives of the National People's Congress and the media. As a result, the Chinese government formed an inter-agency group to develop a new healthcare reform plan for the country. Unable to settle disputes among various government agencies within the group, the Chinese government contracted nine external organizations to help develop healthcare reform plans in 2007.

However, the government agencies and experts so far have failed to reach an agreement over the country's healthcare reform model, although some principles of the reform were announced just before the end of 2007. What will happen next is likely to be based on the late paramount Chinese leader Deng Xiaoping's famous doctrine, "crossing the river by touching the stones", meaning that many experiments will be launched to test different paths before a final agreement is reached.

The changing direction of the healthcare reform will have overwhelming and comprehensive impacts on the pharmaceutical industry, and is likely to trigger another round of restructuring of the industry. Deng's doctrine may be a pragmatic and effective way to settle differences between government agencies for the time being, the final outcome is hard to predict and may come at high costs.

*Cost-containment Measures* - In its desperate attempts to control the rapidly rising healthcare expenditures, the Chinese government has introduced a matrix of cost-containment measures at national and local levels. These measures, including 23 rounds of price cuts on drug products by the central government, have seriously disturbed the normal operation and profit margin, causing sharp increases in administrative costs and resources, and substantially narrowing the profit margins of pharmaceutical companies, both local and foreign.

*Intensive Competition and Industry Consolidation* - The Chinese pharmaceutical industry, which was once dominated by large state-owned enterprises, slowly disintegrated in the past 25 years into a large number of small enterprises with similar product portfolios. By 1985 there were only 1,377 pharmaceutical manufacturing companies in the country, but the number rose to over 5,000 in 2007 in spite of ongoing consolidation and compulsory GMP implementation.

This has led to intensive competition and to the rise of unethical and illegal practices in

pharmaceutical sales and marketing. Cut-throat competition among local generic drug manufacturers has also resulted in shortening product life spans for generic drug products. Most local pharmaceutical companies are trapped in a vicious circle of low R&D investment, poor innovativeness and product differentiation, price competition and low profitability. Compounded by the effect of government price control and cuts, many pharmaceutical companies are suffering from heavy losses, and most small companies are expected to be out of business in the near future.

The government's strategy to "*support the big, and let go of the small*" in recent years has not produced the desired result. Many large state-owned enterprises have simply become bigger and fatter in size, rather than stronger, more competitive and more profitable. Valuable capital and resources drawn from the government and the stock market have been largely under-utilized without delivering expected performance.

*Rising Conflicts between Local and Multinational Companies* - In the 1980s and early 1990s, local Chinese and multinational pharmaceutical companies had focused on the collaborative parts of their mutual relationships. The honeymoon period was over in the past decade, however, with both sides growing stronger in their own ways and beginning to concentrate more on the competitive parts of their relationships, leading to rising conflicts of interests between the two sides, especially in the area of IPR.

*Rampant Counterfeit Drugs* - AmCham China estimated that between 10% and 15% of drugs sold through the retail channel in China are counterfeits. Not only do counterfeit and fake drugs pose serious public health problems for China, but also the country is now one of the biggest exporters of such products. In the past, drug counterfeiters in China developed poor quality fakes, but today they are producing high quality counterfeit drugs.

#### ***Outlook for the future – cautiously optimistic***

Despite variances in market size estimates among different sources, one thing everyone agrees on is the growth of the Chinese pharmaceutical market. Most forecasts predict the market to grow at between 13% and 18% annually between 2006 and 2010.

These growth predictions are supported by an official estimate by the Development Research Center of China's State Council that based on current trends, health spending in the country is set to rise to 7-8% of GDP by 2010 from 5.7% in 2004, thus spurring further pharmaceutical market growth.

2007 was a good year in general for the Chinese pharmaceutical industry which was reshuffling and repositioning itself to adapt to market environmental changes. Many positive developments last year will continue to benefit research-based multinationals and larger local companies in 2008. We are likely to see more growth this year, but companies need to remain prudent because many structural problems in China's healthcare sector remain to be tackled with and the direction and implementation of the healthcare reform may simply change overnight the ways business is being done today.

SMEI forecasted that the total output value of the Chinese pharmaceutical industry in 2008 will grow by 19% to 20% to reach CNY 740 billion to CNY 760 billion (US\$99



billion to US\$101 billion).

On the other hand, IMS projected that the combined market of China, Brazil, Mexico, South Korea, India, Turkey and Russia was expected to grow by 12% to 13% in 2007 to \$85 billion to \$90 billion. Prescription drug sales in China, Brazil, Mexico, Turkey and other emerging economies will account for 25% of the global market in 2008.

The three biggest drivers for future drug consumption growth are: 1) sharp increase of government funding in healthcare, 2) continued expansion of the rural, suburban and urban community healthcare markets, and 3) favorable government policies and cleanup of the urban pharmaceutical market by recent regulatory corrections offer lucrative expansion opportunities to well-positioned larger and innovative companies.

Despite anticipated growth, we believe that the future outlook of the Chinese pharmaceutical industry in 2008 will continue to be heavily influenced by new government policies in areas such as healthcare reform, drug pricing, drug registration, basic medical insurance and healthcare administration.

As the importance of China's pharmaceutical industry grows and its bond with the world fortifies, its future fate will no longer be isolated but instead, will insert wide-ranging impacts on the global pharmaceutical industry and market.

In conclusion, I would borrow a fairly recent Chinese proverb to describe the challenges and future outlook facing the pharmaceutical industry in China: "*while the future is bright, the path to it is twisty with zigzags*".